Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» giroctocogene fitelparvovec
giroctocogene fitelparvovec
Months after exiting clinical hold, Pfizer readies to resume dosing in phase 3 gene therapy trial
Fierce Biotech
Fri, 09/23/22 - 10:50 am
Pfizer
clinical trials
hemophilia A
gene therapy
FDA
giroctocogene fitelparvovec
Another Pfizer gene therapy is free of FDA hold, but delay continues
Fierce Biotech
Tue, 05/3/22 - 10:53 pm
Pfizer
FDA
clinical trials
hemophilia A
gene therapy
giroctocogene fitelparvovec
Sangamo Therapeutics
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525
Drugs.com
Wed, 10/7/20 - 11:33 pm
Pfizer
Sangamo Therapeutics
genomics
clinical trials
hemophilia A
giroctocogene fitelparvovec
SB-525
Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3
Fierce Biotech
Thu, 06/18/20 - 10:38 am
Pfizer
Sangamo BioSciences
hemophilia A
clinical trials
gene therapy
giroctocogene fitelparvovec
